Free Trial
→ The investigation Porter spent tens of thousands to document (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$138.62
-4.0%		$172.78
$123.00
▼
$260.19
$7.28B0.86792,333 shs267,677 shs
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$72.23
-2.0%		$104.49
$28.66
▼
$126.38
$7.89B0.541.47 million shs220,136 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$14.81
+0.5%		$12.99
$11.36
▼
$15.67
$12.36B0.312.54 million shs387,476 shs
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$29.00
-0.7%		$39.80
$25.92
▼
$42.81
$3.42B0.842.35 million shs201,349 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-3.26%+11.22%-7.64%-32.43%+2.49%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-1.10%+2.90%-37.43%-35.61%-5.97%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.41%+1.51%+15.40%+20.00%+6.34%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
-0.85%+9.20%-30.49%-39.51%-34.56%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$138.62
-4.0%		$172.78
$123.00
▼
$260.19
$7.28B0.86792,333 shs267,677 shs
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$72.23
-2.0%		$104.49
$28.66
▼
$126.38
$7.89B0.541.47 million shs220,136 shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$14.81
+0.5%		$12.99
$11.36
▼
$15.67
$12.36B0.312.54 million shs387,476 shs
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$29.00
-0.7%		$39.80
$25.92
▼
$42.81
$3.42B0.842.35 million shs201,349 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-3.26%+11.22%-7.64%-32.43%+2.49%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
-1.10%+2.90%-37.43%-35.61%-5.97%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-0.41%+1.51%+15.40%+20.00%+6.34%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
-0.85%+9.20%-30.49%-39.51%-34.56%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.86
Moderate Buy$267.5893.03% Upside
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
2.50
Moderate Buy$139.5093.13% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.17
Hold$492.903,229.28% Upside
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
2.57
Moderate Buy$60.20107.59% Upside

Current Analyst Ratings Breakdown

Latest SUPN, RDY, CORT, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/9/2026
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageBuy$47.00
11/4/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold (C) ➝ Hold (C+)
11/4/2026
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOverweight$47.00
11/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$284.00 ➝ $272.00
11/4/2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$165.00 ➝ $173.00
11/4/2026
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageStrong-Buy
11/4/2026
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$67.00 ➝ $87.00
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOutperform
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$256.00 ➝ $239.00
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetEqual Weight$247.00 ➝ $249.00
11/3/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$295.00 ➝ $273.00
(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M11.42N/AN/A$2.00 per share69.31
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$963.65M8.20$0.87 per share82.56$7.62 per share9.48
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.58B3.45$0.85 per share17.52$4.87 per share3.04
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$865.11M3.96$2.68 per share10.83($0.51) per share-56.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.06N/A37.87N/A-18.18%-198.73%-22.03%N/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$99.65M$1.2756.7919.84N/A16.53%22.56%17.83%N/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$456M$0.3740.0125.093.078.56%7.91%5.29%1/22/2027 (Estimated)
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$210M$3.588.107.670.5932.75%-418.04%42.96%N/A

Latest SUPN, RDY, CORT, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
$0.84$1.01+$0.17$1.01$339.13 million$340.47 million
11/2/2026Q3 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.6343-$0.25+$0.3843-$0.25$249.19 million$259.69 million
10/29/2026Q3 2026
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$0.49$0.35-$0.14$0.35$217.56 million$208.60 million
10/24/2026Q2 26/27
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.0968$0.12+$0.0232$0.12$894.94 million$903.89 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.060.41%+6.96%16.22%N/A
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/AN/AN/AN/AN/A

Latest SUPN, RDY, CORT, and AXSM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/16/2026
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
special$8.1310/30/202611/6/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1.21
1.42
1.34
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
N/A
3.00
2.94
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.03
1.93
1.40
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A
0.61
0.50

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
93.61%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
20.70%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
8.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
92552.60 million41.76 millionOptionable
Corcept Therapeutics Incorporated stock logo
CORT
Corcept Therapeutics
730109.44 million86.79 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,527834.67 million817.98 millionOptionable
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
827118.04 million108.00 millionOptionable

Recent News About These Companies

Bank of America Initiates Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)
November 11 at 1:43 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31190974
Supernus (SUPN) Stock Still Looks Undervalued As Its 127% 5 Year Run Continues
November 10 at 5:35 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/supernus-supn-stock-still-looks-061100855.html
Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London
November 10 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/10/3399532/19871/en/supernus-inc-to-participate-in-the-2026-jefferies-global-healthcare-conference-in-london.html
Supernus undervalued after Indivior merger, says Bank of America
November 9, 2026  |  ca.finance.yahoo.comhttps://ca.finance.yahoo.com/news/supernus-undervalued-indivior-merger-says-184500799.html
This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
November 9, 2026  |  benzinga.comhttps://www.benzinga.com/analyst-stock-ratings/initiation/26/11/63047576/this-supernus-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday?utm_source=snapi
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Picked Up by Analysts at Bank of America
November 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-supernus-pharmaceuticals-nasdaq-supn-stock-picked-up-by-analysts-at-bank-of-america-2026-11-09/
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Has Average Price Target of $63.50 According to Brokerages
November 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-supernus-pharmaceuticals-inc-nasdaq-supn-stock-has-average-price-target-of-6350-according-to-brokerages-2026-11-07/
Cantor Fitzgerald Forecasts Strong Price Appreciation for Supernus Pharmaceuticals (NASDAQ:SUPN) Stock
November 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31181587
Supernus, Inc.(NasdaqGS:SUPN) added to NASDAQ Composite Index
November 5, 2026  |  marketscreener.comM
Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to Hold at Zacks Research
November 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-supernus-pharmaceuticals-nasdaq-supn-cut-to-hold-at-zacks-research-2026-11-05/
Jefferies Financial Group Begins Coverage on Supernus Pharmaceuticals (NASDAQ:SUPN)
November 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-jefferies-financial-group-begins-coverage-on-supernus-pharmaceuticals-nasdaq-supn-2026-11-05/
Supernus Pharmaceuticals (SUPN) After Its Indivior Merger Looks Undervalued
November 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/supernus-pharmaceuticals-supn-indivior-merger-141813995.html
Supernus Pharmaceuticals (NASDAQ:SUPN) Given New $87.00 Price Target at Cantor Fitzgerald
November 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-supernus-pharmaceuticals-nasdaq-supn-given-new-8700-price-target-at-cantor-fitzgerald-2026-11-04/
Supernus Pharmaceuticals Sends $473 Million to Shareholders
November 3, 2026  |  247wallst.comhttps://247wallst.com/cards/supernus-pharmaceuticals-is-handing-shareholders-473-millio-supn-dividend-payouts-01m6h4vy4t2kf63dtewtn83pnf
What Changes For Supernus Pharmaceuticals (SUPN) After Its Nasdaq Delisting And Merger?
November 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/changes-supernus-pharmaceuticals-supn-nasdaq-191544399.html
Supernus Pharmaceuticals (SUPN) Stock May Be Undervalued After ONAPGO Exclusivity
November 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/supernus-pharmaceuticals-supn-stock-may-222205530.html
Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year Low - Here's Why
November 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-supernus-pharmaceuticals-nasdaq-supn-sets-new-1-year-low-heres-why-2026-11-03/
Supernus Completes Merger With Indivior; Creates CNS-Focused Biopharma
November 3, 2026  |  rttnews.comhttps://www.rttnews.com/3707608/supernus-completes-merger-with-indivior-creates-cns-focused-biopharma.aspx
Profund Advisors LLC Purchases 30,456 Shares of Supernus Pharmaceuticals, Inc. $SUPN
November 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-profund-advisors-llc-purchases-30456-shares-of-supernus-pharmaceuticals-inc-supn-2026-11-03/
Indivior Pharmaceuticals, Inc. completed the acquisition of Supernus Pharmaceuticals, Inc. from group of shareholders in a merger of equals transaction.
November 3, 2026  |  marketscreener.comM
Supernus Pharmaceuticals Completes Merger, Begins Nasdaq Delisting Process
November 2, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/supernus-pharmaceuticals-completes-merger-begins-nasdaq-delisting-process?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$138.62 -5.75 (-3.98%)
As of 12:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corcept Therapeutics stock logo

Corcept Therapeutics NASDAQ:CORT

$72.23 -1.48 (-2.00%)
As of 12:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$14.80 +0.08 (+0.51%)
As of 12:08 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Supernus Pharmaceuticals stock logo

Supernus Pharmaceuticals NASDAQ:SUPN

$29.00 -0.20 (-0.68%)
As of 11:51 AM Eastern

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas